These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 34740228)
21. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227 [TBL] [Abstract][Full Text] [Related]
22. Changes in weight and BMI with first-line doravirine-based therapy. Orkin C; Elion R; Thompson M; Rockstroh JK; Alvarez Bognar F; Xu ZJ; Hwang C; Sklar P; Martin EA AIDS; 2021 Jan; 35(1):91-99. PubMed ID: 33048879 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis. Afify MA; Ahmed IGG; Alkahtani TA; Altulayhi RI; Alrowili ASM; Ghozy S; Bin-Jumah M; Abdel-Daim MM Environ Sci Pollut Res Int; 2021 Mar; 28(9):10576-10588. PubMed ID: 33098001 [TBL] [Abstract][Full Text] [Related]
24. Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. Sun Z; Lan Y; Liang S; Wang J; Ni M; Zhang X; Yu F; Chen M; Zhang H; Yan L; Cai W; Lan G; Ma Y; Zhang F J Antimicrob Chemother; 2022 Mar; 77(4):1119-1124. PubMed ID: 35134966 [TBL] [Abstract][Full Text] [Related]
25. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152 [TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1. Yee KL; Ouerdani A; Claussen A; de Greef R; Wenning L Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745394 [TBL] [Abstract][Full Text] [Related]
27. Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. Martin EA; Lai MT; Ngo W; Feng M; Graham D; Hazuda DJ; Kumar S; Hwang C; Sklar P; Asante-Appiah E J Acquir Immune Defic Syndr; 2020 Dec; 85(5):635-642. PubMed ID: 32925358 [TBL] [Abstract][Full Text] [Related]
28. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Arribas JR Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718 [TBL] [Abstract][Full Text] [Related]
29. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. Saladini F; Giammarino F; Maggiolo F; Ferrara M; Cenderello G; Celesia BM; Martellotta F; Spagnuolo V; Corbelli GM; Gianotti N; Santoro MM; Rusconi S; Zazzi M; Castagna A; Int J Antimicrob Agents; 2023 Mar; 61(3):106737. PubMed ID: 36708743 [TBL] [Abstract][Full Text] [Related]
30. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors. Tabassum T; Azeem SM; Muwonge AN; Frey KM Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197 [TBL] [Abstract][Full Text] [Related]
31. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698 [TBL] [Abstract][Full Text] [Related]
32. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance. Lai MT; Feng M; Xu M; Ngo W; Diamond TL; Hwang C; Grobler JA; Hazuda DJ; Asante-Appiah E Antimicrob Agents Chemother; 2022 May; 66(5):e0222321. PubMed ID: 35491829 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects. Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069 [TBL] [Abstract][Full Text] [Related]
34. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352 [TBL] [Abstract][Full Text] [Related]
35. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220 [TBL] [Abstract][Full Text] [Related]
36. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. Guerrero-Beltrán C; Martínez-Sanz J; Álvarez M; Olalla J; García-Álvarez M; Iribarren JA; Masiá M; Montero M; García-Bujalance S; Blanco JR; Rivero M; García-Fraile LJ; Espinosa N; Rodríguez C; Aguilera A; Vidal-Ampurdanes MC; Martínez M; Iborra A; Imaz A; Gómez-Sirvent JL; Peraire J; Portilla J; Caballero E; Alejos B; García F; Moreno S; J Antimicrob Chemother; 2020 May; 75(5):1294-1300. PubMed ID: 32030406 [TBL] [Abstract][Full Text] [Related]
37. The impact of obesity on doravirine exposure in people with HIV. Zino L; van Bussel LPM; Greupink R; Marneef M; Burger DM; Colbers A AIDS; 2024 Feb; 38(2):267-269. PubMed ID: 38116724 [TBL] [Abstract][Full Text] [Related]
39. [Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Arribas JR Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427 [TBL] [Abstract][Full Text] [Related]
40. Doravirine Use in Treatment-Experienced HIV-Positive Patients. Fulco PP; Herity LB Ann Pharmacother; 2021 Jan; 55(1):127-130. PubMed ID: 32578443 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]